Following on from information provided to NICE by the company in June 2017, the appraisal of Everolimus with exemestane for treating HER2-negative hormone-receptor-positive breast cancer after endocrine therapy [ID965] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 965

Email enquiries

External Assessment Group tbc

Timeline

Key events during the development of the guidance:

Date Update
23 January 2023 Discontinued. Following on from information provided to NICE by the company in June 2017, the appraisal of Everolimus with exemestane for treating HER2-negative hormone-receptor-positive breast cancer after endocrine therapy [ID965] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
23 June 2017 Suspended. Now ID1101
29 February 2016 Draft scope documents

For further information on our processes and methods, please see our CHTE processes and methods manual